4 unknown, 3 active not recruiting, 2 completed, 2 terminated. 8 Phase 2, 4 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 3, Terminated 2, Unknown 2, Completed 1 |
| Phase 3 | 4 | Active not recruiting 2, Unknown 2 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Unknown 1 |
Follow this drug Literature Review of AC protocol trials Research Report on AC protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer AC protocol, Montelukast - Breast Cancer, Doxorubicin Induced Cardiotoxicity | Not applicable | Completed | Damanhour University | 50 | 2023-03-01 | 2026-03-09 |
| Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer Oncotherm EHY-2030, Paclitaxel, Carboplatin - HER2-negative Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Semmelweis University | 71 | 2023-02-20 | 2026-05-15 |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases | Phase 1 | Unknown | Acrotech Biopharma Inc. | 56 | 2020-08-15 | 2020-04-16 |
| Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer Fasting-mimicking diet, Metformin, Preoperative chemotherapy - Triple-negative Breast Cancer | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 30 | 2020-05-05 | 2023-01-18 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide - Breast Cancer Stage II, Breast Cancer Stage III | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 366 | 2019-06-14 | 2026-05-12 |
| Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin Simvastatin, Doxorubicin/cyclophosphamide - Breast Cancer, Stage I Breast Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 34 | 2014-05-20 | 2024-07-09 |
| Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer Paclitaxel/doxorubicin/cyclophosphamide - Locally Advanced HER2-negative Breast Cancer | Phase 2 | Terminated | Instituto do Cancer do Estado de São Paulo | 12 | 2010-08-01 | 2014-05-21 |
| AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer Doxorubicin, Cyclophosphamide, doxorubicin, Capecitabine - Breast Cancer | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 300 | 2010-03-01 | 2011-08-11 |
| Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer Carboplatin and Paclitaxel, Doxorubicin, cyclophosphamide, Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide - Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | The Netherlands Cancer Institute | 310 | 2010-01-01 | 2022-10-12 |
| Treatment With Pazopanib for Neoadjuvant Breast Cancer doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery - Neoplasms, Breast | Phase 2 | Completed | GlaxoSmithKline | 101 | 2009-07-01 | 2014-03-04 |
| Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction Ultrasound, CNB, BCS, Modified Radical Mastectomy - Breast Cancer | Phase 3 | Unknown | Shandong Cancer Hospital and Institute | 4 | 2008-08-01 | 2013-08-06 |
Breast Neoplasms (8) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hyperthermia (1) · Triple Negative Breast Neoplasms (1)
Acrotech Biopharma Inc. (1) · Damanhour University (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · GlaxoSmithKline (1) · Instituto do Cancer do Estado de São Paulo (1) · Peking Union Medical College Hospital (1) · Semmelweis University (1) · Shandong Cancer Hospital and Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The Netherlands Cancer Institute (1)
China (2) · Italy (2) · United States (2) · Belgium (1) · Brazil (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Hungary (1) · Jordan (1) · Netherlands (1) · Poland (1) · Portugal (1) · Spain (1)
Claudio Vernieri, M.D. PhD (1) · Filippo de Braud, Professor (1) · Hans Wildiers, MD, PhD (1) · Karen Smith, MD, MPH (1) · Magdolna Dank, M.D./Ph.D. (1) · Qiang Sun, Master (1) · Sjoerd Rodenhuis, MD (1) · Tao Yang, MD (1) · Wasim Khan, MD (1) · Yong-sheng Wang, MD (1)
PMID 16011702, PMID 16077072, PMID 17438091, PMID 17641361, PMID 18258986, PMID 19097774, PMID 19299237, PMID 19487376, PMID 20157582, PMID 20304629, PMID 20404251, PMID 20586616, PMID 21633166, PMID 21865043, PMID 22323820, PMID 24399079, PMID 24529560, PMID 25092775, PMID 25349301, PMID 25585328, PMID 25937263, PMID 26056183, PMID 26316884, PMID 26438237, PMID 27282289, PMID 27325334, PMID 27872127, PMID 28564564, PMID 29501363, PMID 29577076, PMID 29620997, PMID 29660596, PMID 29713086, PMID 29846104, PMID 29846122, PMID 29873695, PMID 29878040, PMID 30061361, PMID 30100160, PMID 30207593, PMID 30345906, PMID 30479698, PMID 34037241, PMID 37689749, PMID 39694040, PMID 41034674
2009 (1), 2019 (1)